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Heart transplantation is an excellent therapeutic alter-native in end-stage heart failure, allowing a goodsurvival for about half of heart transplant recipientsuntil 15 years after surgical intervention.
However, surgically induced cardiac denervation increases the
resting heart rate in heart transplant recipients through a with-
drawal of the vagal tone. Blunting the heart rate reserve explains
in part the reduced exercise capacity observed after heart trans-
plantation. Additionally, with survival appearing to be inversely
related to the degree of sympathetic activation and in particular to
the noradrenergic drive to the diseased myocardium,1 it might be
very interesting to modulate peptides with cardiac sympathoinhibi-
tory activity after heart transplantation.
Atrial natriuretic peptides (ANPs) might be a good candidate.
Indeed, cardiac natriuretic peptides are important diagnostic and
prognostic tools, and their therapeutic interest is growing because
of their diuretic, natriuretic, and vasodilatory properties. Thus
ANP infusion is useful in poorly responsive oliguria after cardiac
surgery.2 Moreover, importantly, ANPs possess sympathoinhibi-
tory properties that might not only prevent against diuretic-induced
sympathetic stimulation but that also reduce the basal sympathetic
outflow.3 To date, there are several data concerning the renal and
endocrine effect of ANPs after heart transplantation,4 but an even-
tual cardiac sympathoinhibitory action has not been evaluated in
heart transplant recipients, probably because it appeared unlikely
in cardiac-denervated patients.
However, mechanisms located beyond cardiac nerves have
recently been shown to modulate the heart rate control,5 and we
therefore hypothesized that despite cardiac denervation, an in-
crease in endogenous ANP levels might result in cardiac sympa-
thoinhibition after heart transplantation.
Methods and Results
After assessing cardiac innervation in 14 matched control subjects
and heart transplant recipients, we investigated whether the neutral
endopeptidase inhibition–induced increase in ANP levels might be
associated with a reduced heart rate after heart transplantation
during a 4-hour, double-blind, randomized, placebo-controlled study.
As expected, resting heart rate (81.7  3.8 vs 68.3  3.1
beats/min, P  .02), systemic blood pressure (137  5 vs 115 
4 mm Hg, P  .01), and ANP level (19.4  3.6 vs 9.4  1.0
pmol/L, P  .02) were increased in heart transplant recipients
compared with values in control subjects. In opposition to data
obtained in control subjects, heart rate failed to change signifi-
cantly in response to the positional change in heart transplant
recipients (Figure 1).
Unlike after placebo, neutral endopeptidase inhibition (ecado-
tril, 200 mg; Bioprojet, Paris, France) increased circulating ANP
levels (40%  7%, P  .01), and its second messenger, cyclic
guanosine monophosphate (209%  72%, P  .03). It is note-
worthy that systemic blood pressure did not increase but heart rate
was significantly reduced concomitantly with the ANP increase
after neutral endopeptidase inhibition (Figure 2).
Discussion
This study shows for the first time that despite cardiac denervation,
endogenous ANPs possess a cardiac sympathoinhibitory effect
after heart transplantation.
Moving from the lying to the standing position is an accepted
noninvasive method to investigate sinus node innervation. Thus in
innervated control subjects the vagal tone is immediately with-
drawn so that the sinus node is no longer functionally inhibited by
the parasympathetic activity. It results in a sharp and transient
increase in heart rate. The lack of significant heart rate change in
heart transplant recipients demonstrates their cardiac denervation.
Heart rate decrease after ecadotril is likely to be related to ANP
level because in the placebo arm of the study, the lack of change
in ANP level was associated with a lack of heart rate change.
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Figure 1. Heart rate response in controls () and heart-trans-
planted patients (Htx) to an acute position change (PC) from prone
to standing. Differences between groups, P < 0.01 at all times.
Difference with baseline, *P < 0.05, †P < 0.01.
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Concerning the pathways involved, ANPs could decrease the
sympathetic nerve traffic indirectly as a consequence of their
hemodynamic action, through neural mechanisms, or both. How-
ever, the nonhypotensive stimulus required to demonstrate an
inhibitory effect of ANPs on cardiac sympathetic outflow has been
obtained in this study, and thus the heart rate response was unlikely
to be related to modification in arterial baroreceptor loading.3
Thus a direct cardiac sympathoinhibitory effect of ANPs deserves
to be discussed. In cardiac denervated patients only mechanisms
located beyond cardiac nerves, such as reduction in sympathetic
ganglionic neurotransmission or reduced effect of circulating cat-
echolamines on the sinus node, might be involved. This information
cannot be inferred from our data. However, an efferent mechanism,
withdrawal of the inhibitory effects of excess cardiac norepineph-
rine release on vagal modulation of sinoatrial discharge, has been
recently observed in patients with heart failure during -blockade.
This mechanism might also apply after heart transplantation.5
In summary, despite cardiac denervation, increased endogenous
ANP levels have a cardiac sympathoinhibitory effect after heart
transplantation. This opens interesting therapeutic perspectives be-
cause such an effect might be beneficial both in patient survival rate
and quality of life, and these results further support the potential
interest of increasing cardiac hormone levels after heart transplanta-
tion.
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Figure 2. Time course of heart rate in Htx after administration of
placebo () or neutral-endopeptidase inhibition (). Difference with
baseline, *P < 0.05, †P < 0.01.
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